Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

ASH 2014 /
Targeted therapy effective in elderly patients with Philadelphia-positive acute lymphocytic leukaemia

6th - 9th Dec 2014

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 07.12.14
Views: 1832

Dr Oliver Ottmann - Goethe University, Frankfurt, Germany

At a press conference at ASH 2014, Dr Ottmann presents the results from a phase II study that evaluated the efficacy of the tyrosine kinase inhibitor nilotinib in combination with a low-intensity chemotherapy regimen to treat patients 55 or older with newly diagnosed Philadelphia-positive acute lymphocytic leukaemia (Ph ALL).

Read the news story for more.

Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation